Slide Scanner
Digital Pathology
The most complete and suitable end-to-end digital pathology solutions for different customers, including digital pathology equipment, software and AI products.
Molecular Dx Co., Ltd.
WE ARE YOUR SUPPORT PARTNER
Acknowledged specialist in the importation and distribution of laboratory instruments such as chemical reagents, molecular diagnostic reagents in Real-time PCR, FISH, NGS, Fragment Analysis/ CE/ QF-PCR, Optical Genome Mapping (OGM), and software analysis for genomic, cytogenetics, cytogenomic, and pathology.
Why You Should Choose Us
” Leading company in the field of importing and selling of products in the laboratory “
Molecular
We are confident in our ability to serve as your advisor and oversee your lab because our combined experience in molecular research exceeds ten years.
Diagnostic
Good diagnosis depends partly on the quality of the reagents and equipment. Molecular Dx, is delighted to help and support every diagnostic to be more efficient.
We Bring Ideas Diagnostics
Discover how our diagnostics solutions help address some of the world’s greatest healthcare challenges – including yours.
- TEchnique
- Application
- Focus areas
- Instrument & software
Slide Scanner
Breaking Barriers to Precision Oncology
Realtime PCR
Super-ARMS® represents an advancement over traditional ARMS technology achieved through enhanced primer and probe design.
NGS Technology
The AmoyDx HANDLE® technology is a proprietary amplicon-based method for NGS library preparation.
It offers a time-saving and cost-effective protocol that can be completed within 5 hours, requiring just about 1 hour of hands-on time.
AmoyDx® PD-L1 (E1L3N) Assay
AmoyDx® PD-L1 (E1L3N) Assay is a qualitative immunohistochemistry (IHC) assay using monoclonal rabbit anti-PD-L1 clone E1L3N intended for use in the detection of PD-L1 protein in FFPE tissue from multiple tumor types.
Cytogenetics
A comprehensive Digital Cytogenetics Analysis and Workflow
Detecting broken, missing, rearranged, or extra chromosomes provides critical, actionable insights for cancer and genetic diseases, yet traditional cytogenetic methods fall short of discovering key chromosomal aberrations.
The high accuracy of the AI-based automatic chromosome karyotyping application is anticipated to significantly reduce the time spent on preparing karyograms, allowing Cytogenetics professionals to focus more time on chromosome analysis and reporting
Leading the Fight Against Cancer and Rare Disorders
Democratizing Data-Driven Medicine, Together
AI-driven and cloud-powered, we help clinicians to generate real-time, actionable insights for patients with cancer and rare disorders.
We are thrilled to announce our participation in the Pathology Update 2025, organized by the Royal College of Pathologists of Australasia (RCPA), for the very first time! This prestigious event will take place in Australia, showcasing the theme: ‘Excellence in Diagnosis.’
Visit us at Booth #30 to discover how SOPHiA GENETICS is revolutionising the field of precision medicine. As clinicians and pathologists work tirelessly to achieve more accurate diagnoses and improve patient outcomes, we are here to support these efforts with our innovative, data-driven solutions.
SOPHiA GENETICS™ thrilled to be back at this year’s Healthcare Information and Management Systems Society annual meeting. Stop by booth #3460 to meet our team and to learn how our cloud-based SOPHiA DDM™ Platform is empowering clinical researchers to break data silos and improve knowledge sharing. You can also chat with our experts and dem our SOPHiA DDM™ Platform GEN 2. Stay tuned for more information on our Lunch & Learn presentation.
SOPHiA GENETICS™ is thrilled to return for ACMG 2025! Visit us at booth #322 to learn more about our SOPHiA DDM™ and Alamut™ Visual plus platforms for rare and inherited diseases.
Exhibit Theater
Friday, March 21
11:20 am – 11:50 am
Theatre 2
Streamlining genomic complexity with SOPHiA DDM™ and Alamut™ Visual Plus
Elexandra Barboza Arguedas, National Children’s Hospital, CCSS, University of Costa Rica, University of Medical Sciences.
Sevana Yaghoubian, MSc – Senior Director of Product Management, SOPHiA GENETICS.
Discover how our AI-powered platform is transforming germline variant analysis and interpretation, enabling scientists to uncover actionable insights with unmatched accuracy and efficiency. This session showcases the innovative features of the new-generation SOPHiA DDM™ Platform and the latest advancements in Alamut™ Visual Plus, purpose-built to optimize workflows and drive impactful outcomes.
Through the perspective of a medical laboratory scientist, discover SOPHiA DDM™’s capabilities for hereditary cancer and exome applications. Experience how its dedicated features set new standards in the assessment of even the most challenging variants and get an exclusive look at exciting functionalities debuting this year.
SOPHiA GENETICS™ thrilled to be back at AACR 2025! Visit us at booth #2856 to learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform. Discover how it empowers health data interpretation with advanced analytics modules, simplified reporting, and a global community of healthcare institutions. By harnessing the power of AI and multimodal data-driven analytics, we enable you to advance and streamline global access to precision therapies.
Join us at the 14th International Symposium on Minimal Residual Cancer (ISMRC) in Nice, France, where experts gather to explore the latest advancements in liquid biopsy. Discover how SOPHiA GENETICS is transforming cancer care through innovative solutions at the forefront of precision oncology. Visit our booth to learn more and connect with our team—see you there!
SOPHiA GENETICS™ thrilled Charité Mayo Conference 2025! Visit us to learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform. Discover how it empowers health data interpretation with advanced analytics modules, simplified reporting, and a global community of healthcare institutions.
SOPHiA GENETICS™ thrilled to be back at ASCO 2025! Meet our experts at booth #32131 to hear about our biopharma solutions.Learn how we are leveraging our unique AI expertise, to provide an unparalleled offering, unlocking insights from complex data types, driving faster discovery of new stratifying biomarkers, in addition to aiding in the commercialization of precision medicines
FISH
The Gold Standard
Fluorescence in situ hybridization (FISH) is the gold standard technique for the detection of gene copy number changes, including amplifications and deletions critical in the diagnosis and management of cancer.
Fluorescent in situ hybridization (FISH) is considered the “gold standard” technique for detecting chromosomal rearrangements and gene copy number changes within cells particularly in the diagnosis of cancer, due to its ability to visualize specific DNA sequences directly within their cellular context, making it a highly accurate method for identifying genetic abnormalities at the single-cell level